Sanofi Q1 Preview: Building The Pipeline, Improving Business Efficiencies
But Exchange Rate Headwinds
Executive Summary
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.